Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks
- 1 April 2020
- journal article
- editorial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 382 (14) , 1366-1369
- https://doi.org/10.1056/NEJMsb1905390
Abstract
As in the ongoing Covid-19 pandemic, global outbreaks of infectious illnesses often develop quickly and resolve in unpredictable ways. In this report, strategies to develop high-quality evidence to guide the development of new therapies are proposed.This publication has 13 references indexed in Scilit:
- Lassa feverBMJ, 2017
- Master Protocols to Study Multiple Therapies, Multiple Diseases, or BothNew England Journal of Medicine, 2017
- WHO R&D Blueprint: a global coordination mechanism for R&D preparednessThe Lancet, 2017
- Data monitoring committees: Promoting best practices to address emerging challengesClinical Trials, 2017
- A Randomized, Controlled Trial of ZMapp for Ebola Virus InfectionNew England Journal of Medicine, 2016
- Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: Design, procedures, and challengesClinical Trials, 2016
- Issues in data monitoring and interim analysis of trialsHealth Technology Assessment, 2005
- Vaccination against Lyme Disease with RecombinantBorrelia burgdorferiOuter-Surface Lipoprotein A with AdjuvantNew England Journal of Medicine, 1998
- Protective Efficacy of a Live Attenuated Vaccine against Argentine Hemorrhagic FeverThe Journal of Infectious Diseases, 1998
- The alpha spending function approach to interim data analysesPublished by Springer Nature ,1995